CAS 1301214-47-0

Spiro[5H-indazole-5,4'-piperidin]-7(6H)-one,1,4-dihydro-1'-[(2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-

CAS: 1301214-47-0

Formula: C₂₃H₂₇N₅O₂

Purity: 99%

Molecular weight: 405.4928

Ref: IN-DA01DQAT

PF-05175157

CAS: 1301214-47-0

PF-05175157

Purity: ≥98%

Molecular weight: 405.49g/mol

Ref: 54-BUP06391

PF-05175157-d6

CAS: 1301214-47-0

Formula: C₂₃H₂₁D₆N₅O₂

Color and Shape: White To Off-White Solid

Molecular weight: 411.54

Ref: 4Z-P-383002

PF-05175157

CAS: 1301214-47-0

Formula: C₂₃H₂₇N₅O₂

Molecular weight: 405.50

Ref: 4Z-P-383001

1-Isopropyl-1′-(2-methyl-1H-benzo[d]imidazole-6-carbonyl)-4,6-dihydrospiro[indazole-5,4′-piperidin]-7(1H)-one

CAS: 1301214-47-0

Formula: C₂₃H₂₇N₅O₂

Purity: 99%

Molecular weight: 405.502

Ref: 10-F546739

PF-05175157

CAS: 1301214-47-0

PF 05175157 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 27, 33, 23.5, and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2,

Formula: C₂₃H₂₇N₅O₂

Purity: 98% - 99.92%

Color and Shape: Solid

Molecular weight: 405.49

Ref: TM-T7163

PF 05175157

CAS: 1301214-47-0

PF 05175157 is a potent small molecule, orally active inhibitor of fatty acid synthase (FAS) that causes hepatocyte steatosis in vitro and in vivo. PF 05175157 is also an inhibitor of the enzyme stearoyl-CoA desaturase 1 (SCD1), which converts saturated to monounsaturated fatty acids. The compound has been shown to reduce liver and body weight gain in mice fed a high-fat diet, as well as to improve dyslipidemia and hepatic steatosis. PF 05175157 has been evaluated clinically for the treatment of obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. PF 05175157 was granted orphan drug designation for the treatment of pediatric chronic kidney disease by the FDA on June 6, 2015.

Formula: C₂₃H₂₇N₅O₂

Purity: Min. 95%

Molecular weight: 405.49 g/mol

Ref: 3D-BCC21447